Synergy Pharmaceuticals (NASDAQ:SGYP) : Average target price received by Synergy Pharmaceuticals (NASDAQ:SGYP) is $10.75 with an expected standard deviation of $6.01. The most aggressive target on the stock is $15, whereas the most downbeat target is $7. 2 financial analysts are currently covering the stock.
Other Equity analysts have also commented on the company shares. Equity Analysts at the Brokerage Firm, Rodman & Renshaw, maintains their rating on the shares of Synergy Pharmaceuticals (NASDAQ:SGYP). Rodman & Renshaw has a Buy rating on the shares. As per the latest research report, the brokerage house lowers the price target to $15 per share from a prior target of $16. The rating by the firm was issued on May 9, 2016.
Synergy Pharmaceuticals (NASDAQ:SGYP): The stock was completely flat for the day, closing at $3.80 on Thursday. The flat closing masks the intraday volatility in the stock. After opening at $3.83, the stock touched an intraday high of $3.89 and a low of $3.77. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $3.80. The total trading volume on Thursday was 2,281,624.
The company shares have dropped -53.14% from its 1 Year high price. On Jul 7, 2015, the shares registered one year high at $10.15 and the one year low was seen on Mar 23, 2016. The 50-Day Moving Average price is $3.44 and the 200 Day Moving Average price is recorded at $3.81. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Denoyer Bernard, officer (Senior Vice President, Finance) of Synergy Pharmaceuticals, Inc., had unloaded 10,000 shares at an average price of $7.5 in a transaction dated on September 14, 2015. The total value of the transaction was worth $75,000.
Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Companys platform technology is based on the naturally occurring human GI peptide, uroguanylin, a regulator of normal GI physiology. The Companys products include plecanatide, SP-333 and FV-100. The Companys lead product is plecanatide, a guanylate cyclase C (GC-C), receptor agonist, designed to treat GI disorders, primarily chronic idiopathic constipation (CIC), and constipation predominant irritable bowel syndrome (IBS-C). The Company is developing a second-generation GC-C receptor agonist, SP-333, for the treatment of opioid induced constipation (OIC), and for inflammatory bowel disease (IBD). FV-100 is an orally available nucleoside analog. The Companys subsidiaries include Synergy Advanced Pharmaceuticals, Inc., IgX, Ltd and ContraVir Pharmaceuticals, Inc.